Publication | Closed Access

Targeting HER2 + breast cancer cells: Lysosomal accumulation of anti-HER2 antibodies is influenced by antibody binding site and conjugation to polymeric nanoparticles

NanoparticlesNanomedicineAnti-her2 AntibodiesEngineeringProtein NanoparticlesPolymer-drug ConjugateLysosomal AccumulationAntibody EngineeringTumor TargetingMedicineCell BiologyTumor MicroenvironmentTumor BiologyBiomolecular Engineering